JPRN-jRCT2051260087 Rinatabart Sesutecan Gastrointestinal Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Turn a newly registered trial into a decision-ready landscape. This focused report examines JPRN-jRCT2051260087—A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina S) in Participants With Advanced Gastrointestinal (GI) Cancers (RAINFOL-09)—using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, Drug & Asset MCP for mechanism and development context, and Company & Deal Intelligence MCP for sponsor background. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 20 July 2026; publication date: 20 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why JPRN-jRCT2051260087 is a hot trial to watch

Gastrointestinal Neoplasms is increasingly segmented by mechanism, biomarker, treatment setting, geography and endpoint architecture. JPRN-jRCT2051260087 is notable because it evaluates Rinatabart Sesutecan in a Phase 2 design while 固形がんの効果判定規準（RECIST）第1.1版に基づく治験担当医師判定による確定奏効率（ORR） serves as the main decision variable. The critical question is whether the protocol can convert its rationale into a clinically interpretable and operationally credible readout.

PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add development-status, target and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The phase label is only the starting point. Allocation is Randomized, masking is Open Label, and the intervention model is Parallel Assignment. Planned enrollment of 160 participants across Taiwan Province, United States, Italy, Netherlands, South Korea, Germany, United Kingdom, France, Denmark, Australia, Japan, Spain, Belgium shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.

• Primary: 固形がんの効果判定規準（RECIST）第1.1版に基づく治験担当医師判定による確定奏効率（ORR）
• Primary: Confirmed Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by Investigator

Benchmark readouts in the surrounding field

• A Randomized, Dose-ranging, Open-label, Parallel Group Study to Assess the Efficacy, Safety and Pharmacokinetics of Palonosetron HCl Buccal Film Versus IV Palonosetron 0.25 mg for the Prevention of CINV in Cancer Patients Receiving MEC (Phase 2): Complete Acute Response = 4 Participants ; Complete Acute Response = 3 Participants
• Fixed-Dose Netupitant and Palonosetron for Chronic Nausea and Vomiting in Cancer Patients (Phase 2/3): Change in Nausea Numerical Rating Scale (NRS) Between Day 5 and Day 15(Mean): P-Value = 0.98; Change in Nausea Numerical Rating Scale (NRS) Between Day 5 and Day 15(Mean): P-Value = 0.98
• A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of RDX-002 on Postprandial Triglycerides in Patients Discontinuing the Glucagon-like Peptide-1 (GLP-1) Agonists, Semaglutide, or Tirzepatide for the Treatment of Obesity (Phase 2): Incremental Postprandial Triglycerides (TG)(Mean) = 43.81 percent change (Standard Deviation, 92.373); Incremental Postprandial Triglycerides (TG)(Mean) = -51.91 percent change (Standard Deviation, 72.293)

These indexed results are contextual benchmarks, not direct head-to-head evidence. Population, treatment line, endpoint definitions, follow-up and analysis sets may differ. Their value is to clarify the type and magnitude of evidence already visible in the competitive landscape.

Build a living trial monitor: connect to PatSnap MCP Servers and track status changes, endpoint revisions, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: Rinatabart Sesutecan (Phase 3; FOLR1 x Top I)

Company & Deal Intelligence context: Genmab A/S — Denmark — http://www.genmab.com

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
• Sequencing evidence: comparative data after the most relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter probability of success before a headline data release.

Bottom line

JPRN-jRCT2051260087 is a focused lens on Gastrointestinal Neoplasms development. Its value will be determined by whether Rinatabart Sesutecan can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from indexed benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.